Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate.
about
Infectious human immunodeficiency virus can rapidly penetrate a tight human epithelial barrier by transcytosis in a process impaired by mucosal immunoglobulins.Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice.Genes that induce immunity--DNA vaccines.Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes.Oral microbial ecology and the role of salivary immunoglobulin AOral mucosal immunity and HIV infection: current status.Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1.The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression.Immunoglobulin A antibodies against internal HIV-1 proteins neutralize HIV-1 replication inside epithelial cellsInduction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particlesOral mucosal immunity and HIV/SIV infection.Carbohydrate targets in HIV vaccine research: lessons from failures.Enhanced antitumor efficacy by combination treatment with a human umbilical vein endothelial cell vaccine and a tumor cell lysate-based vaccine.Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine.Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A.Alteration of Polymeric Immunoglobulin Receptor and Neonatal Fc Receptor Expression in the Gut Mucosa of Immunodeficiency Virus-Infected Rhesus Macaques.Salivary and mucosal immune responses to HIV and its co-pathogens.HIV infection and specific mucosal immunity: workshop 4B.Novel OK-432-conjugated tumor vaccines induce tumor-specific immunity against murine tongue cancer.Detection of IgA-binding sites on human immunodeficiency virus type-1 envelope glycoproteins, Gp120 and Gp41.Salivary human immunodeficiency virus (HIV)-1-specific immunoglobulin A in HIV-1-exposed infants in Kenya.Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1.Characterization of V3 loop-Pseudomonas exotoxin chimeras. Candidate vaccines for human immunodeficiency virus-1.8 Br-cAMP enhances both humoral and cell-mediated immune responses induced by an HIV-1 DNA vaccine.Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV.HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals
P2860
Q33547146-439FF980-7258-4F39-A5F4-0EE9B4E9BD28Q33640085-86406F33-0B44-46D1-910B-0C6E378D4982Q33641393-198714FF-1075-492E-B14C-00D91E706004Q33784161-94D41AFA-ADC9-4142-B300-A22503028ED3Q34009973-1C215A0C-8CE0-40AC-A9C7-C1726CD2E66EQ34775263-15E34F3B-9445-4744-B35F-E793BECA624DQ35554157-624A990D-278C-4061-A684-474FFC7589A6Q35591075-5BF548D9-3105-4FCA-84EB-E991A198CE14Q35636425-67A76F04-EC05-45A3-AF01-5083AD36EE77Q35704086-583E8103-7009-49AD-A960-51E76994DD04Q36741771-2E029C7B-C634-4E07-BA60-43E126DC3778Q37773298-B5B2671D-0419-45E2-8DC2-C5CE918DC533Q39138856-19DC67F5-4E08-40CF-94C1-6EF1500E60A8Q39570111-7000DB22-17BB-4245-BE8C-B308CC26B97AQ39933471-6D74CE27-2BAD-45C1-A568-978BCCBE5084Q40010413-34C2277B-071B-4CC1-B472-396E1E4AE20BQ41697056-06F6A3ED-15DE-40F5-A72B-E3DACAF26628Q43994786-3FED5874-9F19-47DA-A6CF-6E09D8770C44Q44529276-4504933F-1A01-4444-8C2A-C6A8DA3E0AB2Q45281480-A3F7AFF7-16A4-445C-B1FD-80AFA5FCD10CQ45394795-9655B153-7579-402F-990A-7D9C65CB08B8Q45753503-8CC35970-3A32-428A-802A-9EE7D3C588A5Q45756775-7EA5B640-AB18-4E6D-8575-9C73527EF0D8Q45867374-10E2153E-988B-4034-94FC-BFEF72DFED5FQ45885655-663B96E7-6D2E-403E-91A7-4620BEFBA732Q57997711-CB0A9F39-0C59-4B6D-A6CE-CACA5E2D1AB1
P2860
Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate.
description
1995 nî lūn-bûn
@nan
1995 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Neutralization of HIV-1 by sec ...... ent peptide vaccine candidate.
@ast
Neutralization of HIV-1 by sec ...... ent peptide vaccine candidate.
@en
type
label
Neutralization of HIV-1 by sec ...... ent peptide vaccine candidate.
@ast
Neutralization of HIV-1 by sec ...... ent peptide vaccine candidate.
@en
prefLabel
Neutralization of HIV-1 by sec ...... ent peptide vaccine candidate.
@ast
Neutralization of HIV-1 by sec ...... ent peptide vaccine candidate.
@en
P2093
P2860
P356
P1433
P1476
Neutralization of HIV-1 by sec ...... ent peptide vaccine candidate.
@en
P2093
Fukushima J
Hamajima K
Sekigawa K
P2860
P2888
P304
P356
10.1038/NM0795-681
P407
P577
1995-07-01T00:00:00Z
P6179
1051157466